Nanogen, Inc. (Nasdaq: NGEN), developer of molecular and rapid diagnostic products, announced today that it has signed a licensing and supply agreement with Scandinavian Gene Synthesis (SGS) for use of the Company’s proprietary MGB Probe technology and synthetic nucleic acid chemistries including dyes and quenchers for use in human in vitro diagnostic testing. Under the […]

Company Provides Additional Details on SEQureDx Trisomy 21 Technology Performance Data SAN DIEGO–Sequenom, Inc. (NASDAQ: SQNM – News) today announced new data showing the discovery of DNA methylation markers for Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome) and Trisomy 13 (Patau syndrome) and identification of chromosome RNA-SNP markers for early detection of Trisomies 18 […]

Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, announced today it has signed a nonexclusive license with Roche Diagnostics for the use of Response Genetics’ patented PCR analysis to assess human epidermal growth factor type 2 (HER2) gene expression. The accurate measurement of HER2 gene […]

Evogen, Inc., announced today the launch of its first molecular diagnostics and detection instrument providing innovative ultra-rapid PCR amplification and analysis. The compact EvoCycler™ HD12 is significantly more affordable than comparable instruments with numerous performance advantages. In conjunction with the highly sensitive and specific HyBeacons® PCR chemistry, recently licensed from LGC, Ltd., Evogen now offers […]

Targets Diagnosis and Early Detection of Alzheimer’s and Parkinson’s Diseases OMAHA, Neb. and HOUSTON, Tex., Feb. 2, 2009 — Transgenomic, Inc. (OTC BB: TBIO.OB) and Power3 Medical Products, Inc. (OTC BB: PWRM) today announced they have finalized a transaction, pursuant to their signed Letter of Intent announced December 2, 2008 (see “Transgenomic Signs Letter of […]

Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash SAN DIEGO, Calif., Jan 30, 2009 — – Tepnel Brings Gen-Probe Current and Future Growth Opportunities in Transplant Diagnostics and Genetic Testing, Accelerates European Expansion Strategy – Gen-Probe Incorporated (Nasdaq: GPRO), a pioneer and leader […]

Collaboration with Leading Maternal-Fetal Medicine Physician Group Signifies Further Step Toward Commercializing Trisomy 21 Test SAN DIEGO–Sequenom, Inc. (NASDAQ:SQNM – News), today announced a collaboration with Obstetrix Medical Group, to provide the Sequenom Center for Molecular Medicine (SCMM) with samples for a study to further evaluate its novel, noninvasive prenatal test to assess Down syndrome […]

Sequenom, Inc. (NASDAQ: SQNM) today announced that it has named Allan T. Bombard, M.D., to the newly created position of Chief Medical Officer. Dr. Bombard will oversee Sequenom’s clinical and medical affairs, including clinical strategy, operations and clinical advocacy. “Allan has played an instrumental role in the development of our noninvasive prenatal diagnostic division, including […]

Sequenom, Inc. (NASDAQ:SQNM) today announced new positive data from the prospective clinical studies using the Company’s noninvasive SEQureDx™ technology, enabling the detection of fetal aneuploidy from maternal blood. The data presented today consist of 459 new, high prevalence samples from the prospective, blinded studies performed at Sequenom, bringing the total number of samples studied to […]

Sequenom, Inc. (NASDAQ:SQNM) today announced it is terminating its exchange offer to acquire all of the outstanding shares of common stock of EXACT Sciences Corporation (NASDAQ:EXAS) without accepting for exchange or exchanging any shares of EXACT Sciences common stock. Sequenom had previously announced that it would terminate the exchange offer if EXACT Sciences entered into […]